Trial reportAsian Pacific journal of cancer prevention : APJCP2026
Targeting Side Effects Associated with Androgen Deprivation Therapy Using Melatonin: A Randomized Trial on Hot Flashes and Sexual Health in Prostate Cancer Patients.
Trial report in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to examine melatonin as a potential adjunct therapy for managing treatment-related symptoms in prostate cancer patients, particularly those undergoing androgen deprivation therapy (ADT).
methodsIn light of the increasing incidence of prostate cancer among younger males, this randomized, double-blind, placebo-controlled clinical trial was conducted at the Hematology-Oncology Center of Omid Hospital in Isfahan, Iran, between October 2019 and October 2020. Forty-one prostate cancer patients experiencing hot flashes or sexual dysfunction due to ADT were randomly assigned to receive either melatonin (3 mg twice daily) or a placebo for four weeks. Symptom assessment was performed using the Hot Flash Diary, the International Index of Erectile Function (IIEF), and the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire.
resultThe results showed a statistically significant improvement in FACT-P scores within the melatonin group (P < 0.05), while erectile function scores increased modestly in both groups without reaching statistical significance (P > 0.05). The most pronounced effect was observed in the reduction of the frequency of mild hot flashes in the melatonin group, with significant improvements noted by week four (P < 0.05). Melatonin was well tolerated, with no clinically significant adverse events reported. These findings suggest that melatonin may effectively alleviate vasomotor symptoms and enhance the quality of life in prostate cancer patients undergoing ADT. However, its impact on sexual function remains inconclusive.
conclusionFurther large-scale, long-term studies incorporating mechanistic endpoints are needed to validate these findings and inform clinical guidelines for melatonin use in supportive prostate cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.